Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes

Antonio E. Pontiroli, Giancarlo Viberti, Guido Pozza

Research output: Contribution to journalArticlepeer-review


Clofibrate, 3 g/die for 10 consecutive days, significantly reduced arginine-induced IRI release in chemical diabetics and in normal controls, whether of normal body weight or obese. Blood glucose levels were not affected by clofibrate. In agreement with previous findings, it would appear that clofibrate, administered for short periods, does not lead to a decrease in glucose tolerance. However, studies relating to the effect of chronic clofibrate administration in chemical diabetes are needed in order to be sure that prolonged inhibition of IRI secretion does not lead to overt diabetes.

Original languageEnglish
Pages (from-to)107-110
Number of pages4
JournalActa Diabetologica Latina
Issue number3-4
Publication statusPublished - May 1976


  • Arginine
  • Chemical diabetes
  • Clofibrate
  • Insulin secretion
  • Lipids
  • Radio-immunoassay

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes'. Together they form a unique fingerprint.

Cite this